Frontage Laboratories, Inc establishes a QWBA Center of Excellence (COE) in Exton PA
Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services, has established a Quantitative Whole‑Body Autoradiography (QWBA) Center of Excellence (COE) at our Exton PA facility.
Frontage develops a 3 in 1 multiplex PK assay for evaluation of hydroxy-chloroquine, chloroquine and azithromycin in human plasma to support COVID-19 clinical trials
In the battle against COVID-19, Frontage Bioanalytical, a contract research organization (“CRO”) providing integrated, science-driven, product development services, is first to announce development of potential cocktail PK assay for hydroxy-chloroquine, chloroquine and azithromycin in human plasma.
Frontage Announces the Appointment of Michael J. Potchoiba, M.S to Head the QWBA-Center of Excellence in Exton, PA.
Frontage Laboratories, Inc., is pleased to announce the appointment of Michael J. Potchoiba, M.S to head the QWBA-Center of Excellence in Exton, PA.
Frontage Laboratories, Inc. Response to COVID-19 (May 2020)
Dear Valued Clients and Partners:
I hope this email finds you and your families doing well and staying safe and healthy during these difficult times. At Frontage, despite some modifications to how we operate, our commitment to our clients remain as strong as ever.
Frontage Appoints Dr. Chengwei Fang as Vice President of China Bioanalytical Services
Frontage Laboratories, Inc., announces the appointment of Dr. Chengwei Fang as Vice President, China Bioanalytical Services. In this role, Dr. Fang will be responsible for the overall leadership and strategic growth of Frontage China bioanalysis and supporting teams (PM, QC).
Frontage Appoints Dr.Xiuxiu Cheng as Chief Scientific Officer of China CMC
On April 13, 2020, Frontage Laboratories (Suzhou) Co., Ltd., a Frontage company, announced that Dr. Cheng XiuXiu has joined the CMC (Chemistry, Manufacturing, and Control) Department of Frontage China, and holds the post of chief scientist officer (CSO), and is fully responsible for the product research and Development Department in Suzhou, China.
Frontage Expands Drug Metabolism & Pharmacokinetic (DMPK) Services by Acquiring Biotranex
Exton, Pennsylvania, 01 April, 2020 – Frontage Holdings Corporation ( “Frontage” or the “Group”, 1521.HK), a contract research organization (“CRO”) providing integrated, science-driven research, analytical and development services with presence in both North America and China, today announced Frontage Laboratories, Inc.("Frontage Labs"), a wholly-owned subsidiary of the Group, entered into an equity purchase agreement with third party individuals. According to the agreement, Frontage Labs will purchase the entire equity interest in Biotranex, LLC (“Biotranex”) owned by the individual third parties.
Frontage Holdings Announces 2019 Annual Results
Revenue grew by 20.8% to US$100.4 million
Net profit grew by 64.0% to US$18.4 million
Adjusted net profit1 grew by 28.7% to US$21.4 million
Future contracted revenue increased by 48.6% to US$109.5 million
New lab space of 42,000 sq.ft and 10,000 sq.ft for bioanalytical services were expanded in China and US respectively
The planned expansion of a new facility of 71,000 sq.ft used for expanding CMC2 and bioanalytical services in US is on track
CMC service was newly offered in China / Creation of centers of excellences in DMPK was accelerated through acquisitions
Frontage China will add about 215,000 Square Feet of Lab to Expand DMPK and Preclinical Toxicology Services
On March 12, representatives of Frontage Laboratories (Shanghai) Co., Ltd. (“Frontage Shanghai”) and Suzhou Wuzhong Economic and Technological Development Zone Management Committee signed a project cooperation agreement on the leasing of a new research facility. The new laboratory building is located in No. 4 plant of Fumin Phase III High Standard, Wusongjiang Industrial Park, Wuzhong Economic and Technological Development Zone, Suzhou, China, covering an area of more than 215,000 square feet. It will be mainly used for drug metabolism and pharmacokinetic (DMPK) studies and will include an animal facility for non-GLP and GLP PK and toxicology studies.